Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2021 - 09 - 29 save search
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Published: 2021-09-29 (Crawled : 13:15) - globenewswire.com
EDIT | $5.5 -0.9% -0.91% 2.3M
|
Health Technology
|
| O: -6.58%
H: 2.45%
C: -13.27%
ongoing phase 1 positive trial phase 2 phase 3
Flora Growth Corp. (NASDAQ: FLGC) Ideally Positioned as Colombia Makes Cannabis Progress
Published: 2021-09-29 (Crawled : 13:00) - globenewswire.com
FLGC 4 | $1.56 -7.14% -7.69% 280K
|
Manufacturing
|
| O: 0.32%
H: 2.26%
C: -5.81%
cannabis growth positive nasdaq
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
FirstService Residential Extends Market Leadership Position in Florida
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
FSV | $149.42 0.01% 0.01% 49K
|
Finance
|
| O: 0.16%
H: 1.24%
C: -1.45%
positive
Fortuna announces positive construction decision for its Séguéla gold Project in Côte d’Ivoire
Published: 2021-09-29 (Crawled : 10:00) - globenewswire.com
FSM | $4.65 3.1% -0.65% 5.3M
|
Non-Energy Minerals
|
| O: -0.49%
H: 0.0%
C: -5.19%
positive
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
Published: 2021-09-29 (Crawled : 05:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -2.59%
phase 1 positive phase 1b urticaria phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.